Procter & Gamble Health Limited has informed the Exchange regarding a press release dated August 01, 2025, titled "Press release for the quarter ended June 30, 2025".
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Procter & Gamble Health Limited announced its Q1 FY26 (quarter ended June 30, 2025) results. Sales came in at ₹333 crores, up 20% compared to the same quarter last year, driven by broad-based growth in both domestic and export businesses. Profit After Tax (PAT) stood at ₹66 crores versus ₹17 crores in the year-ago period, though this sharp jump was significantly aided by a one-time impairment charge that had weighed on the base quarter. Managing Director Milind Thatte described it as a strong start to FY26, highlighting continued momentum from brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The results were approved by the Board of Directors at a meeting held on August 1, 2025.
The 20% sales growth signals healthy underlying demand and is genuinely positive. However, the nearly 4x jump in PAT is largely a base-effect story rather than a pure operational surge, so investors should temper expectations on margin trajectory. Overall, the print is constructive for sentiment on the stock.